Cargando…

Elderly Pancreatic Adenocarcinoma Cancer Patients Could Benefit From Postoperative Chemotherapy

The study aim to investigate whether elderly patients with resectable pancreatic ductal adenocarcinoma (PDAC) could benefit from postoperative chemotherapy. METHODS: This study selects the data of PDAC patients who were diagnosed between 2004 and 2014 from the Surveillance, Epidemiology, and End Res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Bin, Shi, Jinbo, Lu, Wenjie, Wu, Yulian, Dong, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317297/ https://www.ncbi.nlm.nih.gov/pubmed/37165831 http://dx.doi.org/10.1097/MPA.0000000000002214

Ejemplares similares

Could Adjuvant Chemotherapy after Surgery Benefit Elderly Patients with Advanced Gastric Cancer?
por: Jeong, Jin Woon, et al.
Publicado: (2016)

Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate‐adjusted analysis at the pre‐adjuvant chemotherapy timing
por: Fu, Ningzhen, et al.
Publicado: (2022)

Association of dysbindin expression with individualized postoperative prognosis and chemotherapy benefit among patients with gastric adenocarcinoma
por: Qian, Hao, et al.
Publicado: (2021)

An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma
por: Feng, Zengyu, et al.
Publicado: (2021)

Survival benefits and disparities in radiation therapy for elderly patients with pancreatic ductal adenocarcinoma
por: Cao, Bi-Yang, et al.
Publicado: (2023)

Change in neoadjuvant chemotherapy could alter the prognosis of patients with pancreatic adenocarcinoma: A case report
por: Meyer, Alberto, et al.
Publicado: (2021)

Radiomics based on machine learning algorithms could predict prognosis and postoperative chemotherapy benefits of patients with gastric cancer: a retrospective cohort study
por: Xiang, Yilan, et al.
Publicado: (2023)

Survival benefits from postoperative radiation therapy on lymph node positive patients with pancreatic adenocarcinoma
por: Xia, Zuguang, et al.
Publicado: (2016)

Could tumor spread through air spaces benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-institutional study
por: Chen, Donglai, et al.
Publicado: (2020)

Efficacy and Benefit of Postoperative Chemotherapy in Micropapillray or Solid Predominant Pattern in Stage IB Lung Adenocarcinoma: A Systematic Review and Meta-Analysis
por: Xu, Congcong, et al.
Publicado: (2021)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

CD66b(+) neutrophils and α‐SMA(+) fibroblasts predict clinical outcomes and benefits from postoperative chemotherapy in gastric adenocarcinoma
por: Cong, Xiliang, et al.
Publicado: (2020)

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
por: Lee, So Heun, et al.
Publicado: (2023)

Elderly Patients with Nondistant Metastatic Pancreatic Head Adenocarcinoma Cannot Benefit from More Radical Surgery
por: Chen, Li, et al.
Publicado: (2022)

Pancreaticoduodenectomy of Pancreatic Ductal Adenocarcinoma in the Elderly
por: Kang, Chang Moo, et al.
Publicado: (2007)

Adjuvant chemotherapy in elderly patients with pancreatic cancer
por: Nagrial, A M, et al.
Publicado: (2014)

Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study
por: Zhang, Yuchao, et al.
Publicado: (2020)

Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study
por: Kamarajah, Sivesh K., et al.
Publicado: (2021)

Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma—Who Will Benefit from a Secondary Resection?
por: Rosumeck, Nathalie, et al.
Publicado: (2021)

Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?
por: Delma, Mohamed Islam
Publicado: (2020)

Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy
por: Ballhausen, Alexej, et al.
Publicado: (2022)

Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery
por: Rahman, Saqib, et al.
Publicado: (2021)

Chemoradiation After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma is it of Proven Benefit?
por: Garden, O. J.
Publicado: (1999)

Novel Metabolomics Serum Biomarkers for Pancreatic Ductal Adenocarcinoma by the Comparison of Pre-, Postoperative and Normal Samples
por: Zhang, Xiaohan, et al.
Publicado: (2020)

Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma?
por: Khalifa, Mahmoud A, et al.
Publicado: (2006)

Role of Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Could It Be Considered a Predictor of Prognosis?
por: De Simoni, Ottavia, et al.
Publicado: (2023)

Comment on: Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery
por: Liu, Kai, et al.
Publicado: (2022)

Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer
por: Chen, Po-Huang, et al.
Publicado: (2022)

Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients
por: Jin, Yin, et al.
Publicado: (2021)

Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump
por: Zeng, Xian-Liang, et al.
Publicado: (2016)

Elderly patients with stage II gastric cancer do not benefit from adjuvant chemotherapy
por: Guo, Jianping, et al.
Publicado: (2023)

Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma
por: Feng, Zengyu, et al.
Publicado: (2021)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
por: Péron, Julien, et al.
Publicado: (2016)

Prediction of risk and overall survival of pancreatic cancer from blood soluble immune checkpoint-related proteins
por: Pan, Sai, et al.
Publicado: (2023)

Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives
por: Tiwari, Akash, et al.
Publicado: (2018)

Adjuvant chemotherapy could benefit early-stage ER/PR positive mucinous breast cancer: A SEER-based analysis
por: Gao, Hong-Fei, et al.
Publicado: (2020)

Efficacy and Safety of Chemotherapy in Elderly Patients with Unresectable Pancreatic Cancer
por: Kwan, Byung Soo, et al.
Publicado: (2023)

Systematic Review of Single-Agent vs. Multi-Agent Chemotherapy for Advanced Pancreatic Adenocarcinoma in Elderly vs. Younger Patients
por: Lewis, Alison, et al.
Publicado: (2023)

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
por: Guo, Long-Hua, et al.
Publicado: (2020)

Author response to: Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery
por: Rahman, Saqib A, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qc9jd6htkeqp0mf2mer3k5t5ps